ArticleMovement disorders clinical practice2026
Real-World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9-Year Nationwide Analysis in France.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT-A). Real-world evidence on treatment patterns remains limited.
objectiveThis nationwide, population-based study aimed to evaluate trends in BoNT-A use in France between 2015 and 2023, using the French National Hospital Discharge Database (Programme de Médicalisation des Systèmes d'Information, PMSI).
methodsPatients were classified into four categories (dystonia, tremor, myoclonus, and other abnormal movements), based on International Classification of Diseases, 10th Revision (ICD-10). Annual changes in the number of BoNT-A injections and treated patients were analyzed. Treatment adherence and reinjection intervals were also evaluated.
resultsA total of 51,861 patients received BoNT-A therapy. Dystonia was the predominant indication (44,913; 86.6%). Tremor accounted for 3690 patients (7.1%), other abnormal movements for 2423 (4.7%), and myoclonus for 835 (1.6%). Between 2015 and 2023, BoNT-A injections increased from 49,829 to 53,828 (+8.0%) and treated patients from 20,023 to 21,489 (+7.3%). While dystonia showed minimal growth in patient numbers (+0.6%), tremor and myoclonus increased substantially (+132.1% and +179.7%, respectively). Repeat BoNT-A injections were highest in dystonia, with 71.8% of patients receiving ≥3 injections and 57.9% receiving ≥5 injections in total. Median reinjection intervals ranged from 112 days in dystonia to 133 days in myoclonus.
conclusionsDystonia remains the leading indication for BoNT-A in France, with high treatment adherence. The marked growth in tremor and myoclonus underscores the expanding therapeutic role and diversification of BoNT-A use across hyperkinetic movement disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.